Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.

Novo Nordisk (NVO) stock draws mixed views from Wall Street analysts after the obesity drugmaker cut its 2025 outlook for the ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

U.S.-listed shares of Novo Nordisk (NVO) fell sharply for a second straight day Wednesday, this time after Bank of America ...

Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...

We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer ...

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.